CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Celularity Inc. - CELU CFD

    0.2008
    1.71%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0069
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 0.2043
    Open* 0.1992
    1-Year Change* -87.45%
    Day's Range* 0.1992 - 0.2053
    52 wk Range 0.19-1.85
    Average Volume (10 days) 373.50K
    Average Volume (3 months) 12.69M
    Market Cap 39.09M
    P/E Ratio -100.00K
    Shares Outstanding 190.95M
    Revenue 15.14M
    EPS -0.52
    Dividend (Yield %) N/A
    Beta 0.17
    Next Earnings Date Nov 24, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 0.2008 0.0016 0.80% 0.1992 0.2053 0.1992
    Dec 7, 2023 0.2043 -0.0049 -2.34% 0.2092 0.2092 0.2012
    Dec 6, 2023 0.2092 -0.0023 -1.09% 0.2115 0.2117 0.2052
    Dec 5, 2023 0.2092 0.0000 0.00% 0.2092 0.2108 0.2092
    Dec 4, 2023 0.2123 -0.0119 -5.31% 0.2242 0.2242 0.2121
    Dec 1, 2023 0.2207 -0.0021 -0.94% 0.2228 0.2277 0.2093
    Nov 30, 2023 0.2096 -0.0096 -4.38% 0.2192 0.2193 0.2092
    Nov 29, 2023 0.2097 -0.0176 -7.74% 0.2273 0.2273 0.2072
    Nov 28, 2023 0.2238 0.0045 2.05% 0.2193 0.2282 0.2183
    Nov 27, 2023 0.2313 0.0221 10.56% 0.2092 0.2329 0.2092
    Nov 24, 2023 0.2072 0.0015 0.73% 0.2057 0.2122 0.2057
    Nov 22, 2023 0.1992 -0.0047 -2.31% 0.2039 0.2122 0.1942
    Nov 21, 2023 0.2039 0.0047 2.36% 0.1992 0.2184 0.1895
    Nov 20, 2023 0.2050 0.0057 2.86% 0.1993 0.2057 0.1932
    Nov 17, 2023 0.2047 -0.0004 -0.20% 0.2051 0.2089 0.1942
    Nov 16, 2023 0.1953 -0.0039 -1.96% 0.1992 0.2027 0.1923
    Nov 15, 2023 0.1992 -0.0020 -0.99% 0.2012 0.2101 0.1912
    Nov 14, 2023 0.2115 -0.0062 -2.85% 0.2177 0.2203 0.1942
    Nov 13, 2023 0.2143 -0.0049 -2.24% 0.2192 0.2243 0.2053
    Nov 10, 2023 0.2174 0.0072 3.43% 0.2102 0.2224 0.2092

    Celularity Inc. Events

    Time (UTC) Country Event
    Friday, March 29, 2024

    Time (UTC)

    20:00

    Country

    US

    Event

    Q4 2023 Celularity Inc Earnings Release
    Q4 2023 Celularity Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 17.975 21.335 0 0 0
    Total Operating Expense 43.575 130.394 4.21996 0.56434 0.0011
    Other Operating Expenses, Total -126.277 -41.145 4.21996 0.56434 0.0011
    Operating Income -25.6 -109.059 -4.21996 -0.56434 -0.0011
    Net Income Before Taxes 14.205 -100.098 -2.43865 3.1812 -0.0011
    Net Income After Taxes 14.192 -100.118 -2.6303 2.51297 -0.0011
    Net Income Before Extra. Items 14.192 -100.118 -2.6303 2.51297 -0.0011
    Net Income 14.192 -100.118 -2.6303 2.51297 -0.0011
    Income Available to Common Excl. Extra. Items 14.192 -100.118 -2.6303 2.51297 -0.0011
    Income Available to Common Incl. Extra. Items 14.192 -100.118 -2.6303 2.51297 -0.0011
    Diluted Net Income 14.192 -100.118 -2.6303 2.51297 -0.0011
    Diluted Weighted Average Shares 149.83 67.0573 8.6787 8.01544 31.25
    Diluted EPS Excluding Extraordinary Items 0.09472 -1.49302 -0.30307 0.31352 -0.00004
    Diluted Normalized EPS 0.11879 -1.49302 -0.30307 0.31352 -0.00004
    Interest Income (Expense), Net Non-Operating 0.365 -2.839 1.78131 3.74554
    Revenue 17.975 21.335
    Cost of Revenue, Total 19.665 9.653
    Gross Profit -1.69 11.682
    Selling/General/Admin. Expenses, Total 66.021 71.341
    Research & Development 78.363 88.353
    Depreciation / Amortization 2.193 2.192
    Unusual Expense (Income) 3.61 0
    Other, Net 39.44 11.8
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 2.938 3.935 4.129 4.135 3.776
    Total Operating Expense 45.414 67.805 -13.356 9.781 -0.399
    Other Operating Expenses, Total -85.164 4.743 -52.836 -33.243 -45.047
    Operating Income -42.476 -63.87 17.485 -5.646 4.175
    Interest Income (Expense), Net Non-Operating -1.038 -0.161 0.21 0.108 0.041
    Other, Net -4.435 0.014 6.752 10.32 43.627
    Net Income Before Taxes -47.949 -64.017 24.447 4.782 47.843
    Net Income After Taxes -47.949 -64.017 24.434 4.799 47.826
    Net Income Before Extra. Items -47.949 -64.017 24.434 4.799 47.826
    Net Income -47.949 -64.017 24.434 4.799 47.826
    Income Available to Common Excl. Extra. Items -47.949 -64.017 24.434 4.799 47.826
    Income Available to Common Incl. Extra. Items -47.949 -64.017 24.434 4.799 47.826
    Diluted Net Income -47.949 -64.017 24.434 4.799 47.826
    Diluted Weighted Average Shares 176.564 155.365 185.957 150.546 151.312
    Diluted EPS Excluding Extraordinary Items -0.27157 -0.41204 0.1314 0.03188 0.31608
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS 0.33898 -0.22131 0.1508 0.03188 0.31608
    Revenue 2.938 3.935 4.129 4.135 3.776
    Cost of Revenue, Total 0.802 2.003 5.247 7.213 3.179
    Gross Profit 2.136 1.932 -1.118 -3.078 0.597
    Selling/General/Admin. Expenses, Total 12.826 13.934 19.08 14.907 15.574
    Research & Development 8.604 16.951 10.99 20.351 25.349
    Depreciation / Amortization 0.546 0.541 0.553 0.553 0.546
    Unusual Expense (Income) 107.8 29.633 3.61
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 33.502 59.1 0.35929 1.00916 0.02471
    Cash and Short Term Investments 13.966 37.24 0.3147 0.91701 0.02471
    Cash 0.3147 0.91701 0.02471
    Total Assets 401.066 414.128 292.156 291.605 0.17446
    Other Long Term Assets, Total 38.161 17.912 0 0.00165 0.14975
    Total Current Liabilities 62.088 26.225 3.40987 0.22909 0.15056
    Payable/Accrued 3.40987 0.21021 0.00056
    Accrued Expenses 13.77 7.34 0
    Notes Payable/Short Term Debt 37.603 0 0 0 0
    Other Current Liabilities, Total 4.905 6.517 0 0.01888 0.15
    Total Liabilities 202.165 314.71 14.223 11.0416 0.15056
    Total Long Term Debt 0 28.085 0 0 0
    Total Equity 198.901 99.418 277.933 280.564 0.0239
    Common Stock 0.015 0.012 272.934 275.565 0.00086
    Additional Paid-In Capital 844.373 763.087 5.11752 2.48726 0.02414
    Retained Earnings (Accumulated Deficit) -645.496 -663.681 -0.11842 2.51187 -0.0011
    Total Liabilities & Shareholders’ Equity 401.066 414.128 292.156 291.605 0.17446
    Total Common Shares Outstanding 148.921 124.308 35.9375 35.9375 31.25
    Prepaid Expenses 6.213 4.668 0.03421 0.09215
    Long Term Investments 291.797 290.595
    Other Liabilities, Total 140.068 260.39 10.8125 10.8125
    Total Receivables, Net 6.966 5.233 0.01038
    Deferred Income Tax 0.009 0.01 0.0006
    Cash & Equivalents 13.966 37.24
    Accounts Receivable - Trade, Net 8.755 5.233
    Total Inventory 5.308 9.549
    Other Current Assets, Total 1.049 2.41
    Property/Plant/Equipment, Total - Net 88.715 90.625
    Property/Plant/Equipment, Total - Gross 109.046 105.404
    Accumulated Depreciation, Total -20.331 -14.779
    Goodwill, Net 119.694 123.304
    Intangibles, Net 120.994 123.187
    Accounts Payable 5.81 9.317
    Current Port. of LT Debt/Capital Leases 0 3.051
    Capital Lease Obligations 0 28.085
    Treasury Stock - Common 0 0
    Other Equity, Total 0.009
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total Current Assets 18.037 25.004 33.502 63.097 75.453
    Cash and Short Term Investments 3.084 8.532 13.966 42.649 37.996
    Cash
    Total Receivables, Net 4.884 5.165 6.966 8.372 6.633
    Prepaid Expenses 4.331 5.823 6.213 6.837 6.161
    Total Assets 246.419 362.416 401.066 437.116 429.337
    Long Term Investments
    Other Long Term Assets, Total 40.49 39.763 38.161 39.094 17.913
    Total Current Liabilities 64.976 66.458 62.088 69.219 32.939
    Payable/Accrued
    Notes Payable/Short Term Debt 16.816 30.945 37.603 39.255 0
    Total Liabilities 127.918 206.788 202.165 272.881 279.187
    Total Long Term Debt 17.027 4.745 0 0 0
    Other Liabilities, Total 45.906 135.576 140.068 203.652 246.238
    Total Equity 118.501 155.628 198.901 164.235 150.15
    Common Stock 0.018 0.017 0.015 0.014 0.014
    Additional Paid-In Capital 873.557 862.457 844.373 833.915 824.865
    Retained Earnings (Accumulated Deficit) -757.462 -709.513 -645.496 -669.93 -674.729
    Total Liabilities & Shareholders’ Equity 246.419 362.416 401.066 437.116 429.337
    Total Common Shares Outstanding 180.817 165.03 148.921 144.524 142.384
    Cash & Equivalents 3.084 8.532 13.966 42.649 37.996
    Accounts Receivable - Trade, Net 4.884 5.165 6.966 8.372 6.633
    Total Inventory 5.738 5.484 5.308 5.239 24.663
    Other Current Assets, Total 1.049
    Property/Plant/Equipment, Total - Net 85.724 87.135 88.715 90.074 90.567
    Property/Plant/Equipment, Total - Gross 109.653 109.288 109.046 108.524 107.923
    Accumulated Depreciation, Total -23.929 -22.153 -20.331 -18.45 -17.356
    Goodwill, Net 90.061 90.061 119.694 123.304 123.304
    Intangibles, Net 12.107 120.453 120.994 121.547 122.1
    Accounts Payable 12.448 8.755 5.81 9.216 10.226
    Accrued Expenses 33.401 24.559 13.77 18.507 20.482
    Current Port. of LT Debt/Capital Leases 0 0 0
    Other Current Liabilities, Total 2.311 2.199 4.905 2.241 2.231
    Capital Lease Obligations 0 0 0
    Deferred Income Tax 0.009 0.009 0.009 0.01 0.01
    Treasury Stock - Common 0
    Other Equity, Total 2.388 2.667 0.009 0.236
    Long Term Debt 17.027 4.745
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 14.192 -100.118 -2.6303 2.51297 -0.0011
    Cash From Operating Activities -137.876 -110.096 -1.18101 -1.09783 -0.00054
    Changes in Working Capital -17.976 -11.083 3.22834 0.13639 0.00056
    Cash From Financing Activities 119.838 98.562 288.839 0.02525
    Financing Cash Flow Items 26.766 97.924 -0.51087 0.00025
    Issuance (Retirement) of Stock, Net 53.872 0.638 289.5 0.025
    Net Change in Cash -23.274 -17.437 -0.60231 0.8923 0.02471
    Deferred Taxes -0.001 -1.353 0.00226 -0.00165
    Non-Cash Items -143.527 -6.359 -1.78131 -3.74554
    Cash Taxes Paid 0 0 0.21865 0.651
    Cash From Investing Activities -5.236 -5.903 0.5787 -286.849
    Other Investing Cash Flow Items, Total 0 0.3 0.5787 -286.849
    Issuance (Retirement) of Debt, Net 39.2 0 -0.15
    Cash From Operating Activities 9.436 8.817
    Cash Interest Paid 0 0.146
    Capital Expenditures -5.236 -6.203
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -64.017 14.192 -10.242 -15.041 -62.867
    Cash From Operating Activities -14.995 -137.876 -108.291 -70.571 -34.253
    Deferred Taxes -0.001 0 0
    Non-Cash Items 18.988 -143.527 -93.37 -55.15 30.002
    Cash Taxes Paid 0 0 0
    Changes in Working Capital 27.671 -17.976 -11.676 -4.983 -3.672
    Cash From Investing Activities -3.209 -5.236 -4.457 -2.894 -1.454
    Other Investing Cash Flow Items, Total 0 0 0
    Cash From Financing Activities 12.759 119.838 118.153 74.214 46.495
    Issuance (Retirement) of Debt, Net 3.376 39.2 39.2 0
    Net Change in Cash -5.445 -23.274 5.405 0.749 10.788
    Cash From Operating Activities 2.363 9.436 6.997 4.603 2.284
    Capital Expenditures -3.209 -5.236 -4.457 -2.894 -1.454
    Financing Cash Flow Items 8.947 26.766 27.246 27.477
    Issuance (Retirement) of Stock, Net 0.436 53.872 51.707 46.737 46.495
    Cash Interest Paid 0.251
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Genting Bhd Corporation 15.7439 30062779 0 2023-06-20 LOW
    Hariri (Robert J) Individual Investor 14.9109 28472010 9357585 2023-10-05 MED
    Starr International Company, Inc. Investment Advisor 8.0029 15281389 0 2023-06-30 LOW
    Celgene Corporation Corporation 6.26 11953274 0 2023-04-24 LOW
    Lung Biotechnology Inc Corporation 4.1733 7968848 0 2022-12-31
    C.V. Starr & Co., Inc. Insurance Company 4.0014 7640693 0 2023-06-30 LOW
    Sorrento Therapeutics, Inc. Corporation 2.6449 5050427 -6307158 2023-10-05 HIGH
    Armistice Capital LLC Hedge Fund 2.4315 4643000 -4587770 2023-06-30 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.3544 2586291 -387483 2023-06-30 LOW
    Kehler (Dean C) Individual Investor 1.1045 2109065 199921 2023-06-14 LOW
    Diamandis (Peter) Individual Investor 0.6656 1270921 199921 2023-06-14 LOW
    Kilcoyne (Adrian) Individual Investor 0.6154 1175000 875000 2023-07-14 HIGH
    Sculley (John) Individual Investor 0.5072 968515 199921 2023-06-14 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.4594 877133 -281999 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.403 769451 -2380129 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 0.4026 768809 768809 2023-06-30 HIGH
    Louis-Dreyfus Family Office LLC Investment Advisor 0.3771 720040 0 2022-09-30
    Biltmore Family Office, LLC Investment Advisor 0.1912 365000 0 2023-06-30 LOW
    Glover (Bradley) Individual Investor 0.1839 351192 -2884 2023-04-13 MED
    von Eschenbach (Andrew Charles) Individual Investor 0.1571 299921 199921 2023-06-14 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Celularity Inc. Company profile

    About Celularity Inc

    Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic T cells engineered with a chimeric antigen receptor (CAR) (CAR-T) cells, natural killer (NK) cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, infectious and degenerative diseases. It has four placental-derived allogeneic cell types: T cells, unmodified NK cells, genetically modified NK cells and ASCs, which resulted in four key cell therapeutic programs: CyCART-19, CYNK-001, CYNK-101 and APPL-001, focused on six initial indications. Its CyCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the CD19 receptor. CYNK-001 is developing for the treatment of acute myeloid leukemia (AML), a blood cancer, and for glioblastoma multiforme (GBM), a solid tumor cancer, and COVID-19.

    Financial summary

    BRIEF: For the six months ended 30 June 2021, Celularity Inc revenues was not reported. Net income totaled $30.9M vs. loss of $5.7M. Net income reflects Change in fair value of warrant liabilit increase from $6.6M (expense) to $34.5M (income), Unrealized gain on marketable securities decrease from $42K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.16 to $0.70.

    Industry: Bio Therapeutic Drugs

    170 Park Ave
    FLORHAM PARK
    NEW JERSEY 07932
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Gold

    2,004.85 Price
    -1.180% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    XRP/USD

    0.70 Price
    +2.450% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading